African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials

被引:33
|
作者
Powell, IJ
Meyskens, FL
机构
[1] Wayne State Univ, Karmanos Canc Inst, Dept Urol, Detroit, MI 48201 USA
[2] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA
[3] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA
关键词
D O I
10.1016/S0090-4295(00)00968-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The risk of prostate cancer diagnosis among African Americans is 66% greater than among European American men. For African Americans with a family history of hereditary prostate cancer the increased risk of diagnosis is even greater. Thus, this population should be a prime target for chemoprevention strategies. In addition to the higher incidence of prostate cancer among African Americans compared with other populations, the mortality of prostate cancer among this high-risk population is significantly greater than 100% compared with other populations, thus further demonstrating the need for chemoprevention in this target population. Autopsy studies and clinical findings support the argument that prostate cancer exhibits more aggressive biological behavior and perhaps more rapid growth among African Americans compared with European Americans. It is hypothesized that genetic and epigenetic factors may be responsible for a more rapid growth rate among African Americans compared with other populations. Accumulating evidence indicates that a diet high in fat content is closely associated with prostate cancer progression. Investigators have reported that fat intake and percentage of energy from fat were highest in African Americans, followed by European Americans, Japanese Americans, and Chinese Americans, In conclusion, African Americans are an important target population to include in chemoprevention trials that include dietary factors as preventive agents.
引用
收藏
页码:178 / 181
页数:4
相关论文
共 50 条
  • [1] Chemoprevention in African American Men With Prostate Cancer
    Kumar, Nagi B.
    Pow-Sang, Julio M.
    Spiess, Philippe E.
    Park, Jong Y.
    Chornokur, Ganna
    Leone, Andrew R.
    Phelan, Catherine M.
    [J]. CANCER CONTROL, 2016, 23 (04) : 415 - 423
  • [2] Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men
    Courtney, P. Travis
    Deka, Rishi
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Salans, Mia A.
    Nelson, Tyler J.
    Kumar, Abhishek
    Luterstein, Elaine
    Yip, Anthony T.
    Nalawade, Vinit
    Parsons, J. Kellogg
    Kader, A. Karim
    Stewart, Tyler F.
    Rose, Brent S.
    [J]. CANCER, 2021, 127 (23) : 4403 - 4412
  • [3] Personalizing the Management of Men with Intermediate-risk Prostate Cancer
    D'Amico, Anthony V.
    [J]. EUROPEAN UROLOGY, 2013, 64 (06) : 903 - 904
  • [4] Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Diven, Marshall A.
    Tshering, Lhaden
    Ma, Xiaoyue
    Hu, Jim C.
    Barbieri, Christopher
    McClure, Timothy
    Nagar, Himanshu
    [J]. JAMA NETWORK OPEN, 2024, 7 (08)
  • [5] Outcomes for Men with Intermediate-risk Prostate Cancer on Active Surveillance
    Courtney, P. T.
    Deka, R.
    Cherry, D. R.
    Nelson, T. J.
    Luterstein, E.
    Salans, M. A.
    Yip, A. T. T.
    Nalawade, V.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S121 - S122
  • [6] UTILITY OF ONCOTYPE DX IN MEN WITH INTERMEDIATE-RISK PROSTATE CANCER
    Cantu, Miguel
    Golan, Ron
    McCarthy, Hiral
    Scognamiglio, Theresa
    McClure, Timothy
    Barbieri, Christopher
    Robinson, Brian
    Khani, Francesca
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E207 - E207
  • [7] Insignificant disease among men with intermediate-risk prostate cancer
    Hong, Sung Kyu
    Vertosick, Emily
    Sjoberg, Daniel D.
    Scardino, Peter T.
    Eastham, James A.
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1417 - 1421
  • [8] Insignificant disease among men with intermediate-risk prostate cancer
    Sung Kyu Hong
    Emily Vertosick
    Daniel D. Sjoberg
    Peter T. Scardino
    James A. Eastham
    [J]. World Journal of Urology, 2014, 32 : 1417 - 1421
  • [9] Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
    Cooperberg, Matthew R.
    Cowan, Janet E.
    Hilton, Joan F.
    Reese, Adam C.
    Zaid, Harras B.
    Porten, Sima P.
    Shinohara, Katsuto
    Meng, Maxwell V.
    Greene, Kirsten L.
    Carroll, Peter R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 228 - 234
  • [10] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
    Sherer, Michael, V
    Leonard, Austin J.
    Nelson, Tyler J.
    Guram, Kripa
    De Moraes, Gustavo Rodrigues
    Javier-Desloges, Juan
    Kane, Christopher
    McKay, Rana R.
    Rose, Brent S.
    Bagrodia, Aditya
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67